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Many of the nutrients beneficial for intestinal health are present in normal 
foods, but their normal daily intake may be too low to exert optimum 
effects on intestinal barrier function and immune status. Evidence from 
laboratory and farm production animals strongly supports dietary supple-
mentation with additional nutrients and nutraceuticals, however research 
in horses remains scarce and inconclusive. Careful consideration of the 
outcome desired for horses in care, together with the types of nutraceuti-
cals available, is needed to develop effective strategies for maintenance 
of healthy intestinal barrier function and for treatment of various leaky 
gut syndromes in horses. This review presents these issues in the context 
of what is known about the effects of nutraceutical-type nutrients on the 
mammalian (including equine) g.i. tract and intestinal microbiome with 
the aim of providing suggestions for the equine situation.
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1. Introduction
Leaky gut syndrome denotes a range of conditions whereby the barrier functions of the intestinal system have been compromised, thereby making 
the intestinal wall permeable to molecules and sub-
stances that should not freely enter into the interior of 
the horse. There are numerous, intimate relationships 
between the gastrointestinal tract (GIT), immune system 
and the microbiota within the GIT. The purpose of this 
review is to highlight a number of nutrients and nutra-
ceuticals that are of importance to GIT health, particu-
larly in maintaining healthy GIT barrier function and in 
repairing barrier function [1].
Barrier function refers to the fact that the GIT keeps 
ingested matter outside of the interior of the animal [2-4]. 
The healthy GIT is supposed to act like a true physical 
barrier because much of what is ingested, and much of 
the digesta and microbiome within the GIT, are in fact 
harmful if they enter the body. As with any structure, its 
integrity is a reflection of how well it is maintained, and 
failure to maintain barrier function of the GIT results 
in a leaky gut, an increased permeability of the barrier 
formed by intestinal epithelial cells (Figure 1).
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Figure 1a. Schematic representation of a portion of 
intestinal wall showing the physical barrier formed by 
intestinal epithelial cells (IECs) and the mucous barrier 
that overlies the IECs in intestinal lumen. Tight junctions, 
adherens junctions, and zonula ocludens junctions nor-
mally hold IECs tightly together
Figure 1b. Left panel: Healthy IEC layer with no leaks. 
Right panel: Intestinal pathogens attack IEC structures, 
weakening the physical barrier, which can result in in-
flammation and leak through the weakened barriers. Leak 
can occur between cells (paracellular pathway) or through 
severely damaged cells
For the purposes of this review we have consid-
ered nutrients to be the molecules arising from the 
digestion of traditional feedstuffs such as forages and 
grains; these include amino acids, peptides, mono- and 
disaccharides, free fatty acids, electrolytes, minerals, 
water and some vitamins. Nutraceuticals, in contrast, 
are ingredients that can be added to feeds, to the feed 
as a supplement, or on its own that impart to the horse 
benefits beyond those normally attributed to nutrition-
al molecules. Nutraceutical ingredients are derived 
mainly from plants, animals, fungi and bacteria and a 
nutraceutical product may contain a blend of ingredi-
ents derived from one or more of these main sources. A 
nutraceutical may also be a product of digestion, butyr-
ate for example which is produced by some gut micro-
biota but can also be supplemented to the normal diet 
specifically for the purpose of improving GIT barrier 
function. Probiotics and prebiotics may also be used as 
nutraceuticals. Probiotics are living microorganisms, 
typically bacteria and yeasts, that must survive the acid 
environment of the stomach and when in the intestine 
contribute beneficial effects to one or more of the GIT 
microbiome, to the mucous layer, to immune system 
cells and to intestinal epithelial cells (IECs). Examples 
includes some bacterial strains of lactobacillus, aci-
dophilus and yeast strains of Saccharomyces cerevisiae. 
Prebiotics are compounds that provide nutritional sub-
strate for beneficial microbiota (commensal bacteria) 
which thereby result in increased growth, proliferation 
and metabolism of beneficial microbiota. The products 
of beneficial microbiota contribute to GIT health by a 
number of mechanisms including antibiotic effects on 
pathogenic microbiota, augmenting the molecular de-
fenses of the mucous barrier, production of molecules 
that signal other commensal bacteria, dendritic cells 
of the innate immune system as well as the intestinal 
epithelial cells themselves. Examples of prebiotics in-
cludes plant, yeast or bacterial cell wall material – an 
example are beta-glucans derived from oats or from 
fungi.
2. Nutrients and Nutraceuticals with Demon-
strated Benefits
Suggested approaches that may be used when feeding 
supplements to horses for the purposes of correcting a 
leaky gut, or better still to prevent a leaky gut from occur-
ring, include:
(1) Provide nutrients and nutraceuticals that are specific 
to the needs of the IECs; 
(2) Provide nutrients and nutraceuticals that are specific 
to the needs for maintaining / repairing the mucosal barri-
er that lines the luminal (interior) surface of IECs;
(3) Provide beneficial microbiota (probiotics) to aug-
ment or repopulate the commensal microbiome within the 
small intestine, cecum and lower GIT -- these can include 
microbes that destroy undesirable GIT microbes;
(4) Provide nutrients and nutraceuticals that are specific 
to the health and proliferation of the commensal microbi-
ome (prebiotics). 
An effective strategy for correction of leaky gut will 
employ these four approaches, while effective strategies 
for maintaining healthy GIT barrier function in stressed 
horses will use at least three of these four approaches. A 
balance of these, and the absence of nutritional gaps, is 
important, when designing effective strategies.
There are two main ways in which the GIT can be 
nourished: (1) from within the lumen (exterior to the 
body); and (2) from the arterial blood supply in the basal 
lamina (interior of the body) side of the barrier. This ar-
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ticle focuses on providing nutrients on the luminal side 
(feedstuffs) and that will have effects on the GIT without 
having to be absorbed into the body by the IECs. Supple-
ments such as vitamins, amino acids, nucleic acids, car-
bohydrates and fatty acids of the correct types and in the 
right balance may have beneficial effects on GIT mucous 
layer and IEC growth and proliferation [5]. Some of these 
are included within complete feed rations and premium 
feeds, but there often remain nutritional gaps that result in 
inadequate defense against factors contributing to leaky 
gut.
Luminal nutrients and nutraceuticals serve a number of 
important functions including (1) providing fuel to (L-glu-
tamine) to IECs; (2) stimulating the growth and prolifer-
ation of new IECs by their interactions with existing cells 
(galactose and 3-O-methyl-d-glucose); (3) stimulating the 
release of gut hormones from the distal small intestine, 
cecum and colon; (4) molecular signaling functions to 
increase or decrease nutrient transport systems, i.e. for 
glucose or amino acids; and (5) stimulation of intestinal 
mucus production [1,6-8].
Some of the main sites of action of various nutrient 
and nutraceutical classes are presented in List 1. The di-
saccharides sucrose, maltose and lactose are more potent 
than monosaccharides such as glucose, galactose and 
fructose for stimulating growth and proliferation (tro-
phic effect) of IECs, and this trophic effect requires the 
hydrolysis (breakdown) of disaccharides to the mono-
saccharides [9]. This trophic effect is pronounced within 
the small intestine, the primary site for absorption of nu-
trient molecules coming from dietary sources of carbo-
hydrates, fats and protein. Different amino acids such as 
ornithine, L-glutamine, histidine, valine, glycine appear 
to stimulate growth and proliferation by different mecha-
nisms from each other and from carbohydrates. The IECs 
use 20% of the extracted amino acids for mucosal pro-
tein synthesis (the intestinal mucous is rich in proteins) 
and the remainder for many other metabolic processes 
including providing fuel for oxidative energy produc-
tion with the IECs. Some long-chain triglycerides (fats) 
enhance adaptive responses in the small intestine and 
the effect is more pronounced in the presence of some 
long-chain free fatty acids [10]. One of the smallest mole-
cules, the short chain fatty acid butyrate, is produced by 
beneficial GIT microbes and it can also be supplemented 
in the diet.  Butyrate plays a crucial role in maintaining 
the tight junctions between IECs throughout the length 
of the GIT, is involved in mucosal barrier integrity [11-13]. 
Dietary water- and fat-soluble vitamins (mainly vitamins 
A, C, D and riboflavin) are also required for intestinal 
epithelial cell growth and proliferation [7,14-16].
L-arginine – IEC growth, barrier function, immuno-
stimulant
Beta-glucans – anti-parasitic, anti-bacterial, anti-oxi-
dant, anti-inflammatory
Butyrate – IEC tight junctions, mucosal barrier, energy 
source, immune system, nervous system
Disaccharides – energy source for transport systems 
and trophic effects
Fatty acids – oleic acid, linoleic acid, palmitic acid are 
closely associated with immunological function of the in-
testinal mucosa
L-glutamine - IECs energy source, protein synthesis, 
growth, proliferation, repair, barrier function, immuno-
stimulant
L-threonine – mucosal barrier
List 1. Key sites of action of specific GIT-beneficial 
nutrients and nutraceuticals
2.1 Amino Acids
Amino acids can be provided in the form of proteins 
sources from the diet, or as supplements of specific amino 
acids. Providing amino acids solely from dietary protein 
sources can result in an oversupply of some amino acids 
and inadequate provision of other, GIT-important amino 
acids and is not recommended in cases of suspected leaky 
gut syndrome. Three amino acids worthy of consideration 
for maintenance gut health and barrier integrity and for in-
clusion into a strategy for treatment of leaky gut syndrome 
are L-glutamine, L-arginine and L-threonine.
2.1.1 L-Glutamine
L-glutamine is a highly digestible amino acid that has 
many important nutritional, immune function, perfor-
mance and general health benefits in healthy and unwell 
mammals. These include regulation of cellular gene ex-
pression, neuronal excitability, protein turnover, cellular 
metabolism, immunity and acid-base balance. For the 
GIT, L-glutamine can be considered an "essential" ami-
no acid [17-19] and barrier function is dependent on dietary 
L-glutamine availability [20].
The proteolysis or breakdown of dietary protein and 
peptide sources provides about 87% of L-glutamine 
within the body, while the remaining 13% arises from 
synthesis within the body [21]. However most (>90%) of 
the L-glutamine absorbed from the lumen of the small in-
testine does not enter the portal circulation and is used by 
IECs. Most of the uptake occurs in the small intestine [22-
23] but dietary L-glutamine is transported into IECs along 
the entire length of the GIT. Up to two-thirds being is 
used to provide energy within these cells along the entire 
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length of the GIT19. Among the various types of IECs, the 
absorptive columnar epithelial cells of the small intestine 
is the major site of L-glutamine extraction and oxidative 
energy (ATP) production [25].
Numerous researchers have shown that dietary L-glu-
tamine supplementation is important to maintain a normal 
intestinal barrier against pathogens and preserve mucosal 
integrity [20,27-30]. Within the GIT L-glutamine is involved in 
the regulation of cell growth and numerous cellular func-
tions including cell / tissue regeneration. L-glutamine is one 
of the most important amino acids for IECs as an important 
energy source, for its ability to build protein within the 
cells, for its regulatory roles in the metabolic pathways of 
other amino acids such as ornithine, citrulline, L-arginine, 
and proline [31-33]. Removal of L-glutamine by starvation 
of cultured intestinal mucosal cells prevents cell growth 
and proliferation, and results in a breakdown of tight- and 
adherens junctions with loss of barrier function, leading 
to a leaky gut. L-Glutamine supplementation decreases 
intestinal permeability and preserves gut mucosa integrity 
in an experimental mouse model [28]. Dietary L-glutamine 
is necessary for normal intestinal mucosal growth and for 
maintenance of the intestinal mucosal integrity [7].
Inadequate L-glutamine supply is associated with im-
paired function of TIT-associated immune function, and 
L-glutamine been shown to be essential for lymphocytes 
(which are unable to synthesize L-L-glutamine) and other 
rapidly dividing cells, such as gut mucosa and bone mar-
row stem cells [27,32]. High rates of extraction and utiliza-
tion of L-glutamine by leukocytes, and by lymphocytes in 
particular, has led to the classification of L-glutamine as 
an immunostimulant [33]. 
Table 1. Benefits of dietary sources of L-glutamine to 
support growth and health (from Ruth and Field [29])
• serves as a precursor and energy substrate for immune and epithelial 
cells;
• is important for intestinal development and function and for maintain-
ing the integrity of the gut barrier, the structure of the intestinal mucosa, 
and redox homeostasis;
• supports proliferative rates and reduces enterocyte apoptosis;
• protects against pathogenic bacterial damage to intestinal structure 
and barrier function;
• lowers inflammatory response and increases immunoregulatory cyto-
kine production; and
• improves the proliferative responses and numbers of intestinal im-
mune cells.
2.1.2 L-arginine
The amino acid L-arginine is also highly digestible (85 
– 92%) within the small intestine and is taken up and 
metabolized within IECs, in addition to active absorp-
tion into the blood. When dietary L-arginine is low (less 
than 1% of diet) supplementary L-arginine (up to 2% of 
diet) may stimulate growth of intestinal epithelial cells 
[34]. Compared to diets low or absent of L-L-arginine, 7 
days of consuming a diet having 2% L-arginine resulted 
in preservation of intestinal barrier function within mice 
when bolus E. coli was introduced into the stomach [36]. 
This confirms an earlier study in rats receiving 300 and 
600 mg L-arginine per day, where an effective barrier to 
E. coli was maintained in the presence of an induced low-
er small intestine (illeal) obstruction [37]. This beneficial 
effect appears to be due to a reduction in / modulation of 
inflammatory signaling molecules within the GIT includ-
ing proinflammatory cytokines, and with stimulation of 
immunoglobulin A production [36].
Performance horses are subjected to periods of train-
ing, transport and competition, of which heat and exercise 
stresses contributed to intestinal dysfunction. Exercise 
heat stress results in loss of small intestine barrier function 
and compromised immune responses [38].  L-arginine sup-
plementation (2% of diet) to mice subjected to exercise 
heat stress prevented the increases in intestinal permeabil-
ity and bacterial translocation caused by exertional hyper-
thermia. The authors concluded that “dietary l-L-arginine 
supplementation preserves the integrity of the intestinal 
epithelium during exercise under heat stress”. In the large 
intestine the provision of L-arginine is essential for main-
taining the integrity of the epithelial barrier. L-arginine is 
transported into epithelial cells lining the large intestine 
by the cationic amino acid transporter resulting in the pro-
duction of polyamines that are required for maintaining 
barrier function and for repair of impaired barrier function 
within the large intestine. Within the intestinal immune 
systems, L-arginine also stimulates T cell proliferation 
and activity thus combating inflammation [40,41]. One of the 
beneficial effects of L-arginine is by inducing the immune 
system to stimulate T cell proliferation and activity in 
conditions such as peritonitis and sepsis [41,42].
2.1.3 L-Threonine
The amino acid L-threonine is also highly digestible (84 
– 93%) within the small intestine and is taken up and me-
tabolized within intestinal epithelial cells, in addition to 
active absorption in the blood. Within the small and large 
intestine, L-threonine is oxidized by epithelial cells and 
specifically used for mucin production. L-Threonine is 
one of the nine indispensable amino acids that cannot be 
synthesized to meet body needs in animals and therefore 
must be provided in the diet. Dietary L-threonine imbal-
ance reduced the growth of the small intestine, liver and 
skeletal muscle in young animals, and reduced protein 
synthesis and mucin production in the jejunum of growing 
DOI: https://doi.org/10.30564/vsr.v1i1.1057
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pigs [43]. This translates to an optimum dietary L-threonine 
of about 1% of digestible protein.
In neonates especially, the gastrointestinal tract extracts 
the majority of dietary L-threonine on the first pass to 
maintain synthesis of L-threonine-rich mucins in mucus. 
As dietary L-threonine becomes limiting, this extraction 
must limit protein synthesis in extra-intestinal tissues 
at the expense of maintaining protein synthesis in mu-
cin-producing tissues [44]. These authors concluded that “If 
dietary L-threonine intake is deficient, then muscle growth 
and the functions of other tissues are likely compromised 
at the expense of maintenance of the mucus layer in mu-
cin-producing tissues”.
L-threonine is required by IECs of both the small and 
large intestine to produce the mucin [45] that is such an 
essential component of barrier function and intestinal im-
munity. Mucin, and the L-threonine-requiring cells that 
produce it, form an essential and important part of the 
(enteric) intestinal immune system involved in protection 
from physical and chemical insult [46,47]. Ileal losses of 
L-threonine through mucin contribute to increased L-thre-
onine usage in humans [48] and intestinal mucin production 
is considered a major metabolic fate for L-threonine [49]. 
In addition to its use for mucin and muscle protein synthe-
sis, other major functions of L-threonine include immune 
function, protein phosphorylation, and glycine synthesis, 
as reviewed by [49].
Horses and other animals are routinely challenged by 
pathogenic bacteria that are ingested with foods or acci-
dently. Provision of supplementary L-threonine resulted 
in improved growth performance, health, immunity and 
gastrointestinal function of weaning pigs challenged with 
E. coli [50]. Even small (0.5 g / kg feed) increases in dietary 
L-threonine improved feed intake, overall feed efficien-
cy, intestinal IgA secretion and beneficially regulated the 
population of gut microbiota in growing pigs. In poultry 
it was similarly concluded that L-threonine supplemen-
tation can improve immunity, antioxidant capacity and 
intestinal health [51], building on the earlier work of many 
researchers including Azzam et al. [52] who suggested that 
L-threonine functions as a nutrient immunomodulator in 
maintaining intestinal barrier function.
2.2 Short Chain Fatty Acids
Short chain fatty acids (SFCAs) such as butyrate, propri-
onate and acetate are produced by many types of com-
mensal microbes within the distal small intestine, cecum 
and large intestine. All of these can be used as fuel for 
oxidative metabolism by all cells of the body and some, 
i.e. butyrate, exerts direct effects within the GIT. Micro-
bial fermentation is most commonly associated with the 
hindgut of horses, however, foregut fermentation in horses 
also occurs such that starch fermentation in the foregut 
contributes to the overall response [53]. Fermentation of 
dietary starch in the foregut, cecum and hindgut results in 
the production of lactate, which is used by beneficial GIT 
microbes to produce butyrate. Butyrate has immunomod-
ulatory properties and reduces intestinal [54] and systemic 
inflammation when fed to geriatric horses [55].  Butyrate 
can also be rapidly transported by IECs into the blood 
from which it can be used as an energy source by numer-
ous cells and tissues of the body [56].
Butyrate is a very important molecule within the GIT 
because it has direct inputs into intestinal, immune [7] and 
nervous system physiology and a role in gut-brain com-
munication [57]. An increasing number of studies indicate 
a primary role of butyrate in reinforcing epithelial barri-
er function through signaling within IECs to maintain / 
repair tight junctions [13] and by stimulating increases in 
mucus production [11,58]. Butyrate also contributes to the 
energetic balance of IECs, is involved in the regulation 
of oxidative stress and inflammatory status of cells. [2,12]. 
Changes in diet affects the population of gut microbiota [8] 
and this in turn modulates the peripheral nervous system 
and brain function via what has been termed a microbiota 
gut-brain axis [56]. The effects of intestinal microbiota on 
the nervous system cannot be disassociated from effects 
on the immune system since both systems are in constant 
bidirectional communication. Alterations to the microbial 
population in the GIT may affect the production neu-
rotransmitter molecules such as gamma amino butyric 
acid, and the products of fermentation (SCFAs such as 
butyrate, propionate, and acetate).
Butyrate is produced by ileal, cecal and colonic mi-
crobial fermentation of dietary fibers (complex carbo-
hydrates) present within forage and other feedstuffs [57]. 
While not as important, proprionate and acetate are also 
pleomorphic and positively influence IEC [2] and whole 
body [59] glucose and energy homeostasis. A high abun-
dance of intestinal Bifidobacterium, Lactobacillus and 
Clostridium leptum results in healthy production of butyr-
ate and other SCFAs.  Sodium butyrate supplementation 
is also shown to enhance the GI mucosal growth and high 
carbohydrate improve gastrointestinal functions in piglets 
after weaning [57]. However, when the abundance of SC-
FA-producing microorganisms is low, the result is often 
poor epithelial barrier and tight-junction integrity, a re-
duced ability to repair of epithelial lesions, and a reduced 
ability to combat exercise-associated GI barrier perturba-
tions. Overfeeding of grain is common, and this results in 
elevated cecal and hindgut production of lactate, which 
lowers luminal pH to favour the proliferation of non-bene-
DOI: https://doi.org/10.30564/vsr.v1i1.1057
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ficial microbes and reduces the populations of commensal 
bacteria, therefore lowering the production of butyrate [60].
Because of butyrate’s recognized importance in many 
aspects of healthy GIT function, research has been under-
taken to find effective ways of increasing cecal and hind-
gut butyrate concentrations through dietary supplementa-
tion of butyrate products. Because butyrate is so rapidly 
taken up by many cells, it is necessary to encapsulate the 
butyrate to allow it to travel with digesta into the cecum 
and hindgut. Here, the capsule is degraded, releasing bu-
tyrate which raises luminal concentrations to desired lev-
els where beneficial effects can occur. One such product is 
ButiPearl Z EQ (Kemin Industries) which, after ingestion, 
results in a sustained release of butyrate and provision of 
zinc which is a beneficial cofactor for commensal gut mi-
crobes. This product acts to promote intestinal health and 
barrier function through provision of energy, maintenance 
of tight junctions and mucous production. Studies have 
shown that butyrate supplementation enhances the GI 
mucosal growth and improves several indicators of GIT 
function [3,11-13].
2.3 Beta-glucans
Beta-glucans are polysaccharide cell wall components of 
cereals such as oats, fungi, some yeasts and some bacte-
ria. Beta-glucans present in mushrooms and yeasts exhibit 
β-l,3- and β-l,6-linkages. In barley and oats, the β-l,3- and 
β-l,4-linked water-soluble beta-glucans are predominant 
and account for about 75% of the cell wall dry matter [61]. 
The beta-glucan content of oat bran is about 9% which is 
three times greater than that of oat flour [61]. Beta-glucans 
are a form of dietary fiber that are not degraded in the 
stomach and the small intestine, therefore are delivered to 
the cecum and large intestine where they provide a source 
of non-starch polysaccharides to microbiota [62].
Animal studies using oat beta-glucan have shown uptake 
or interaction with cells of the gastrointestinal tract, with 
benefits including protection against intestinal parasites and 
bacterial infection, anti-oxidant, anti-inflammatory. In vitro 
studies reported effects on cytokine secretion, phagocyt-
ic activity and cytotoxicity of isolated immune cells, and 
activation of the complement system [63]. Reported effects 
in animal studies include a protective effect against an in-
testinal parasite, protection against bacterial infection, and 
a synergistic effect in antibody-dependent cellular cytotox-
icity [64]. Dietary oat beta-glucans have been associated with 
anti-inflammatory, immune-stimulating, and gut microbio-
ta-modulating activities, as well as the ability to beneficially 
modify microbial SCFA production [63, 65].
Dietary supplementation with yeasts or mushrooms 
rich in beta-glucans exhibit immune stimulating effects 
in humans [66-68] and other animals [69]. In animals, dietary 
yeast beta-glucans have reduced the incidence of bac-
terial infections and levels of stress-induced cytokines, 
and  enhanced antineoplastic effects of cytotoxic agents. 
Protective effects toward drug intoxication and ischemia/
reperfusion injury have also been reported [70].  Toxicity 
studies performed on laboratory animals have shown that 
beta-glucans are safe at high dietary inclusion levels (>2 g 
/ kg body mass / day) [71,72].
2.4 Triglycerides (TGs), Free Fatty Acids (FFAs) 
and Polyunsaturated Free Fatty Acids (PUFAs)
TGs, FFAs and PUFAs are dietary fats or lipids and some 
of these beneficially the functions and structures of cells 
and tissues, including those of the GIT. TGs can be com-
prised of both FFAs and PUFAs on a glycerol backbone, 
and TGs are easily broken down into its four molecular 
parts. Intestinal barrier function is directly modified by 
cell membrane lipid content, and therefore providing 
beneficial dietary lipids is important. Rapid increases in 
dietary fats should be avoided as enzyme systems needed 
for lipolysis and transport need to be gradually upregulat-
ed, and sudden changes can result in increased intestinal 
permeability. 
IEC barrier permeability is directly modified by cell 
membrane lipid content and dietary lipids appear to exert 
rapid effects on IEC membrane composition and function. 
This highlights the importance of providing beneficial 
dietary fats. As such, omega-3 polyunsaturated fatty acids 
have been proposed as an adjuvant therapy in animals 
with leaky gut [73,74]. Part of the rationale behind this ap-
proach is that phosphatidylcholine and other phospholip-
ids serve as major components of the intestinal mucus lay-
er and are integral in establishing the gut mucosal barrier. 
Kunisawa et al. [75] showed that dietary palmitic acid and 
its metabolites enhance intestinal IgA responses including 
increased numbers of IgA-producing plasma cells in the 
large intestine. Thus, omega-3 PUFAs have been proposed 
as a nutritional therapy in leaky gut conditions in humans. 
Randomized and controlled clinical trials showed that the 
administration of dietary PUFAs reduces the GIT inflam-
matory activity in ulcerative colitis patients by serving as 
major components of the intestinal mucus layer, generat-
ing and maintaining the protective layer overlying IECs 
and thus helping to re-establish an effective mucosal bar-
rier [76].
The quality and quantity of dietary fat intake is also 
closely associated with immunological function of the 
intestinal mucosa mainly through induction of gut-asso-
ciated lymphoid tissue [77]. Oat oil, sunflour oil, borage oil 
and fish oil are excellent sources of beneficial fatty acids, 
DOI: https://doi.org/10.30564/vsr.v1i1.1057
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including palmitic acid, omega-3 and omega-6 polyun-
saturated fatty acids.  Some oils are high in polyphenol 
and tocopherol antioxidant activities and exert beneficial 
effects on cells and tissues [78]. The unsaturated fatty acids 
oleic acid, linoleic acid, as well as palmitic acid, confer 
beneficial effects on maintaining and restoring intestinal 
health and immunity after various challenges includ-
ing gliadin-induced depletion of intestinal defenses [79], 
Chron’s disease in humans [77], nutritional depletion of 
intestinal defenses [80] and restitution after small bowel 
resection [81]. These fatty acids are highly digestible in the 
small intestine, and also exert direct and indirect effects 
on IEC function and on modulating the intestinal microbi-
ota. Studies using rats have shown that dietary oleic acid 
supplements contributed to maintenance of immunolog-
ical function of the intestinal mucosa [80]. They also exert 
anti-inflammatory activity and may exert trophic effects 
such as cellular proliferation, increased mucosal mass 
and increased mucosal IgA activity [82]. High levels of IgA 
within the intestine protect against pathogenic microor-
ganisms by preventing their passage through the mucosal 
barrier and attachment to IECs, as well as by neutralizing 
their toxins. Their beneficial effects are particularly ev-
ident in vitro studies when used prophylactically in the 
face of disease-causing agents [77]. 
2.5 Probiotics and Prebiotics
Effective nutritional strategies for maintaining a healthy 
GIT rely on more than one approach.  This is mainly due 
to the fact that the GIT tract is a very complex physiolog-
ical system that integrates the physiology and metabolism 
of intestinal epithelial cells (IECs), immune system cells, 
and both beneficial (commensal) and pathogenic micro-
biota dwelling in the GIT. Prebiotics, probiotics, antimi-
crobials and fecal microbial transfaunation continue to be 
explored to manipulate GIT microbiota composition and, 
by doing so, achieve a healthy GIT. 
Gut microbiota dysbiosis, i.e. unfavorable alterations 
in microbiota populations as a whole, are associated with 
acute colitis [83], equine grass sickness [84], laminitis [88] and 
a wide range of other diseases [8]. The microbiota refers 
to the microbes living within the GIT, and these living 
organisms include bacteria, yeasts and fungi and archaea 
(Figure 2). Probiotics and prebiotics work to help restore 
a balanced, favourable gut microbiota. The microbiota is 
unique for each horse, but in healthy horses the phylum 
Firmicutes is predominant (46 – 70%) in feces. Bacteroi-
detes, Proteobacteria, Verrucomicrobia, Actinobacteria, 
and Spirochaetes contribute up to 15% each [86-87]. Micro-
biota dysbiosis is characterized by substantial shifts in the 
phyla as observed in a range of equine gastrointestinal dis-
ease. Healthy horses are abundant in Actinobacteria, Spi-
rochetes, and order Clostridiales while many GIT diseases 
are characterized by increased abundance of Fusobacteria 
[8]. There appears to be little or no difference in the abun-
dance of Lactobacillales (majority of lactic acid-produc-
ing bacteria) between healthy and diseased horses. 
In a healthy horse microbiotal populations are in bal-
ance with respect to one another and with respect to the 
IECs and the immune cells. In a healthy GIT the popula-
tions of beneficial microbiota are high keep the popula-
tions of pathogenic microbiota in check. The pathogenic 
microbiota are so called because some of the products of 
their metabolism is toxic to IECs, immune cells and to 
beneficial microbiota. High starch diets, sudden chang-
es in diet [88], medications, excessive stress and ingested 
pathogens can all result in increased populations of patho-
genic microbiota [89]. One nutritional strategy, therefore, 
is to ensure that the GIT is regularly provided with pro-
biotics that are capable of supporting the populations of 
beneficial microbiota while suppressing the population of 
pathogenic microbiota. Balance is key – it is not desirable 
that all pathogenic microbiota are destroyed.
Figure 2. A microbiome map of the phylla resident in the 
healthy horse GIT. The equine GIT contains more than 
150 different species of microbiota from 27 different phy-
la, of which about 25 species predominate. [87]
Note: From Ericsson et al. (2016) PLoS ONE 11(11): e0166523
Probiotics are simply living biological organisms, 
mainly bacteria and yeasts, that are good for GIT health. 
The ‘pro’ means good or beneficial, the ‘biotic’ means 
alive. A probiotic is not to be confused with a prebiotic, 
which is a compound that is not alive but that serves to 
provide beneficial nutrients to beneficial microbiota in the 
gut.  Inactivated yeasts and bacteria as well as products 
from these organisms may be probiotics. There are numer-
ous ways in which probiotics can be beneficial, including:
(1) Production of molecules that inhibit growth of 
pathogenic microbiota (antibiotic effect)
(2) Production of molecules that provide nutrition for 
IECs
(3) Production of molecules that provide nutrition for 
and / or modulate cells of the innate and acquired immune 
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systems
(4) Production of molecules that provide nutrition for 
other beneficial microbiota
(5) Production of molecules that directly contribute to 
barrier functions of the mucosal layer and of the IEC tight 
junction barrier
(6) Production of molecules that are used as nutrition 
(fuel) by other cells of the body once absorbed by the GIT, 
for example the volatile fatty acids butyrate, propionate 
and acetate
(7) Inhibition or inactivation of pathogenic toxins
(8) Competitive exclusion of pathogenic microbiota
Some of the commonly available and effective pro-
biotics for horses include both bacteria and yeasts when 
used as supplements or as microbial feed additives. The 
most commonly used genera for probiotics, Lactobacil-
lus, Bifidobacterium and Enterococci are normally in low 
abundance in the equine GIT. It is also not required that 
probiotics colonize the GIT in order to obtain beneficial 
effects. While colonization may be considered superior 
to mere survival due to a prolongation of the beneficial 
activity, even transient probiotics may act beyond the pe-
riod of administration. However, in many animals studied 
to date the ability of probiotics to colonize the GIT is not 
host-specific, therefore strains are typically selected on the 
basis of their probiotic properties, and not their species 
of origin. It may also be beneficial that probiotic bacterial 
strains are also antibiotic resistant, particularly when anti-
biotics are needed for post-surgery and injury situations 90.
3. Bacterial Products
Probiotic species commonly used commercially are Bi-
fidobacterium and Lactobacillus and examples of each 
has been briefly described. This will be followed by brief 
consideration of Bacillus subtilis and E.coli. The reader 
is referred to other reviews for more detailed treatments 
of this topic [91,92]. While there is evidence-based research 
supporting positive effects on intestinal barrier function 
and health in laboratory and production animals, results 
obtain to date in healthy and diseased horses remain in-
conclusive.
Different species of Bifidobacterium have had positive 
effects in animal models of intestinal infection and inflam-
mation. For example, mice that received Bifidobacterium 
longum showed an increased number of IgA-producing 
cells in the intestine, and significantly improved survival, 
against Salmonella typhimurium infection [93]. Similar 
results have been obtained in response to C. difficile chal-
lenge [94]. Bifidobacterium bifidum S17 exerted beneficial 
effects on intestinal histology, chemokine, cytokine, and 
inflammatory tissue marker profiles in a murine model of 
colitis [95].
Lactobacillus, of various species, had beneficial effects 
murine models of colitis. L. brevis G-101 induced the ex-
pression of IL-10 in peritoneal macrophages and signifi-
cantly inhibited the expression of inflammatory cytokines 
which was associated with improved intestinal barrier 
function and cell morphology [96]. Heat-killed Lactobacil-
lus brevis SBC8803 (a prebiotic) resulted in improved in-
testinal barrier, attenuated intestinal injury and decreased 
mRNA expression of the proinflammatory cytokines 
TNF-a, IL-1-b, and IL-12 [97]. Application of a medium 
containing secretagogues from a combined probiotic (L. 
plantarum, L. acidophilus, and B. infantis) reduced necro-
tizing enterocolitis-like intestinal injury and improved the 
inflammatory profile [98]. The commercial probiotic mix-
ture VSL#3 (Streptococcus thermophilus, B. longum, B. 
breve, B. infantis, L. acidophilus, L. plantarum, L. casei, 
and L. bulgaricus) reduced inflammation and prevented 
increases in colonic epithelial permeability that were asso-
ciated with maintained (as compared to disrupted) expres-
sion and distribution of junctional proteins [99].
Bacillus subtilis is a naturally occurring species of bac-
teria commonly found in soil, but also present in the GIT 
of many animals including horses. In horses, the Bacillus 
species represent less than 1% of the microbiome, but 
they may play a role that is larger than what their numbers 
indicate. There are many different strains of B. subtilis 
that are used as probiotics in a variety of animals includ-
ing humans and horses. Each different strain will act in 
unique ways, so it is incorrect to state that one strain is 
better than another for every situation. 
The PB6 strain of B. subtilis that was identified in the 
GIT of stressed poultry nearly 20 years ago when found to 
be associated with increased survival of the GIT disease 
necrotic enteritis. This strain has been developed and ex-
tensively tested for function and safety. The mechanism 
of action of strain PB6 appears to be through its ability to 
produce and secrete an active molecule into the GIT that 
retards the proliferation of Clostridium species as well as 
other pathogenic species [100,101].
In poultry with induced necrotic enteritis (using Eime-
ria sp. and C. perfringens) B. subtilis PB6 reduced feed 
conversion ratio, and this was associated with reduced 
intestinal C. perfringens counts, improved villi length and 
increased villi length to crypt depth ratio [102,103]. In neona-
tal pigs receiving formula supplemented with PB6 for 21 
days, compared to controls, treatment decreased the feed 
conversion ratio due to increased villous height and intes-
tinal activities of maltase and sucrase. This was associated 
with upregulation of mRNA and protein abundances of 
zonula occludens-1 and claudin-1 in the ileum evidence 
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of Bacillus proliferation in colonic digesta [104]. Using a 
rat model of induced in inflammatory bowel disease, PB6 
appeared to secrete surfactins (cyclic lipopeptides) with 
anti-bacterial potential that inhibited PLA2, a rate-limit-
ing enzyme involved in the arachidonic acid associated 
inflammatory pathway 101. Ten days of oral PB6 admin-
istration suppressed the colitis as measured by mortality, 
changes in weight gain, colon morphology and reduced 
levels of plasma proinflammatory cytokines.[101]
In many animals, Clostridium species of bacteria are 
associated with gastrointestinal distress, and in horses 
C. difficile is unfortunately all too prevalent and one of 
the most important causes of diarrhea and enterocolitis 
in foals and adult horses [105]. The Clostridium species 
produce toxins that breakdown the structural integrity of 
the mucosal barrier and IECs, resulting in a leaky gut. 
Infection is typically caused by ingestion of spores from 
animal (including equine) feces, contaminated soil from 
the animal hospital environment. Hospitalization and an-
tibiotic treatment are the two major risk factors for the de-
velopment of C. difficile associated disease. The intestinal 
lesions caused by C. difficile produced toxin A and toxin 
B are not distinguishable from the lesions caused by other 
pathogenic bacteria. So detection of fecal toxin A and B 
are diagnostic for C. difficile 105. The strategy of provid-
ing the PB6 strain of B. subtilis routinely as part of the 
horse’s diet may help prevent the occurrence of leaky gut 
or reduce the severity of leaky gut. In an in vitro study of 
five common equine intestinal and respiratory pathogenic 
bacteria (C. difficile, C. perfringens, R. equi, S. equi, Sal-
monella typhimurium) application of PB6 to plated media 
or broth resulted in inhibition of growth of all pathogenic 
species [106].
The probiotic product ColiCure contains a strain of E. 
coli approved for use in Europe to improve fecal consis-
tency in adult horses [107]. Results presented in the EFSA 
report indicate a more rapid improvement in fecal con-
sistency in diarrheic horses treated with Colicure (1 X 10 
[11] CFU daily for three days) than with control diarrheic 
horses. 
4. Yeast Products
The primary probiotic yeasts used are the nonpathogenic 
Saccharomyces cerevisiae and S. boulardii of various 
strains. They are typically used live (probiotics) or heat 
inactivated or dead (prebiotic). Some inactivated yeast 
products also used as prebiotics include those that are rich 
in mannan oligosaccharides and / or beta glucans – both 
of which are associated with nutraceutical benefits in ani-
mals [108].
Research under controlled conditions using laboratory 
animals provide good evidence for efficacy of probiotics 
and prebiotics. Supplementary feeding with Saccharo-
myces strains (S. boulardii and S. cerevisiae UFMG 905) 
have been associated with preservation of intestinal barri-
er integrity and reduce BT in animals [109-111].  In a murine 
model of intestinal obstruction, both viable and heat-killed 
S. boulardii and S. cerevisiae 905 were associated with 
improvement in intestinal morphology, reduced intestinal 
damage, stimulation of intestinal IgA production, and in-
creased cytokine IL-10 after intestinal obstruction [109-110]. 
Daily treatment of mice challenged S. typhimurium with 
S. boulardii prevented weight loss, enhanced survival, 
protected against liver damage and inhibited inflammatory 
signal transduction pathway activation in mice after chal-
lenge [111].
Positive results on intestinal barrier function in various 
laboratory and production animals led to research investi-
gating the efficacy of probiotics and prebiotics in healthy 
horses and in horses with gastrointestinal disease. In a 
randomized blinded placebo-controlled clinical trial the 
efficacy of S. boulardii in treating the diarrhea associated 
with acute colitis in horses was assessed [112]. Acute colitis 
can be caused by several pathogens, making identification 
of a specific cause difficult. Horses receiving S. boulardii 
had a shorter duration of diarrhea and watery diarrhea 
compared to controls, but the duration of loose feces was 
similar in both groups.
When S. boulardii was assessed in horses affected with 
antimicrobial-associated diarrhea no differences were ob-
served between groups (12 horses per group) with respect 
to fecal consistency or cessation of watery diarrhea [113]. 
Also similar between groups were: days to improvement 
in attitude, resolution of leukopenia, return of: appetite, 
normal heart rate, normal respiratory rate, normal tem-
perature. The lack of efficacy was attributed to difficulty 
in standardization of treatment, and a possible lack of 
colonization by S. boulardii because the fecal samples of 
some horses were negative for S. boulardii. In the study 
by Desrocher et al. [112], administration of 10 X 10 [9] CFU 
with the feed twice daily showed viable fecal S. boulardii 
at 5 days, but not at 20 days.  Therefore S. boulardii may 
have beneficial effects but does not appear to colonize the 
ceca and colons of horses [114,115]. Any beneficial effect of 
these yeast probiotics may only persist during the period 
of administration, and therefore consideration needs to be 
given to long-term feeding. 
The safety of commercially available probiotics and 
prebiotics appears to be high, and large amounts and 
repeated dosing do not appear to have harmful effects 
[8,116]. Many commercially available products either have 
successful GRAS and / or EFSA notifications and are 
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thus considered safe by regulatory authorities when used 
as intended in the target species.  In animals, including 
humans, there are reports of extra-intestinal infections 
associated with the use of some products, this may reflect 
translocation of pathogenic material across a leaky gut 
with resulting infection and inflammation [117]. There have 
been no such published reports in horses, even when up 
to three times the manufacturers recommended serving 
amount was used in horses with colic [118]. While research 
in horses remains inconclusive regarding efficacy, re-
searchers and clinicians generally consider probiotics and 
prebiotics as safe for use in healthy and diseased adult 
horses.
5. Summary and Conclusions
This review has highlighted a number of nutraceutical 
and nutritional ingredients that can be supplemented to 
the normal diet of horses with the specific goal of better 
maintaining and / or repairing barrier functions of the 
GIT. These ingredients include specific amino acids, free 
fatty acids, butyrate, probiotics and prebiotics.  Definitive 
in vivo information regarding efficacy of probiotics and 
prebiotics is often lacking in horses, and usage is indicat-
ed from studies using animal models of intestinal disease. 
There is a clear need for both descriptive and mechanis-
tic studies on all aspects of nutraceutical treatments for 
equine leaky gut syndrome.
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